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MethylglyoxalDiabetic patients have increased likelihood of developing breast cancer. Advanced glycation endproducts (AGEs)
underlie the pathogenesis of diabetic complications but their impact on breast cancer cells is not understood. This
study aims to determine the effects of methylglyoxal-derived bovine serum albumin AGEs (MG-BSA-AGEs) on
the invasive MDA-MB-231 breast cancer cell line. By performing cell counting, using wound-healing assay,
invasion assay and zymography analysis, we found thatMG-BSA-AGEs increasedMDA-MB-231 cell proliferation,
migration and invasion through Matrigel™ associated with an enhancement of matrix metalloproteinase
(MMP)-9 activities, in a dose-dependent manner. Using Western blot and ﬂow cytometry analyses, we
demonstrated that MG-BSA-AGEs increased expression of the receptor for AGEs (RAGE) and phosphorylation
of key signaling protein extracellular signal-regulated kinase (ERK)-1/2. Furthermore, in MG-BSA-AGE-treated
cells, phospho-protein micro-array analysis revealed enhancement of phosphorylation of the ribosomal protein
70 serine S6 kinase beta 1 (p70S6K1), which is known to be involved in protein synthesis, the signal transducer
and activator of transcription (STAT)-3 and the mitogen-activated protein kinase (MAPK) p38, which are
involved in cell survival. Blockade of MG-BSA-AGE/RAGE interactions using a neutralizing anti-RAGE antibody
inhibited MG-BSA-AGE-induced MDA-MB-231 cell processes, including the activation of signaling pathways.
Throughout the study, non-modiﬁed BSA had a negligible effect. In conclusion, AGEs might contribute to breast
cancer development and progression partially through the regulation of MMP-9 activity and RAGE signal
activation. The up-regulation of RAGE and the concomitant increased phosphorylation of p70S6K1 induced by
AGEs may represent promising targets for drug therapy to treat diabetic patients with breast cancer.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetes and cancer are major health problems and prevalent
diseases with a globally increasing incidence. Generally, cancer has an
increased metabolism associated with elevated glycolytic rates which
enhance the formation of advanced glycation endproducts (AGEs) [1].ct; AP, Activator protein; BSA,
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signal regulated kinase; FBS,
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44 161 247 6831.AGEs are a group of heterogeneous macromolecules formed during a
non-enzymatic reaction called the Maillard reaction [2]. This Maillard
reaction is responsible for the intermolecular cross-linking between
the reactive carbonyl group of sugars and the nucleophilic amino
group of proteins, lipids or nucleic acids [3,4]. Although this glycation
reaction is a non-speciﬁc biochemical reaction, protein modiﬁcation
results in altered enzyme activity [5], immunogenicity [6], decreases
ligand binding [7], and cross-linking of extracellular matrix proteins,
which cause stiffening [8]. Increased protein glycation has been associ-
ated with several age-related [9] and chronic inﬂammatory diseases
such as cardiovascular diseases [10], Alzheimer's disease [11], stroke,
retinopathy [12], nephropathy [13], neuropathy and cancer [14]. In
addition, AGE formation is often accompanied by increased free radical
activity, which can damage cell membranes and cause gene mutations
resulting in malignant cell transformation [15].
The cellular effects of AGEs are mainly mediated through the receptor
for advancedglycationendproducts (RAGE). RAGE is a 45-kDa transmem-
brane multi-ligand signal transduction receptor belonging to the immu-
noglobulin superfamily, which is highly expressed during embryonic
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adult tissues [16]. In pathological conditions, RAGE expression is induced
by high glucose [17], reactive oxygen species (ROS), external stress, hyp-
oxia [18], pro-inﬂammatorymediators andbyAGE itself [17]. RAGE is also
over-expressed on activated immune cells [19], vascular cells [20] and
cancer cells [21]. AGE–RAGE interactions trigger a diverse array of signal-
ing pathways [22], including mitogen activated protein kinase (MAPK)
such as extracellular-signal regulated kinase (ERK)-1/2 [20], p38 [23]
and c-jun kinase (JNK), that induce the activation of transcription factors
such as nuclear factor kappa B (NF-κB) [24], activator protein (AP)1 and
signal transducers and activators of transcription (STAT)-3 [25]. This is
accompanied by ROS production [26] and by subsequent transcription
and changes in gene expression, which result in tumor growth through
increased cell proliferation [27] and tumor metastasis through stimula-
tion of cell migration and invasion [14]. In addition, matrix metallopro-
teinases (MMPs) and especially gelatinases (i.e. MMP-2 and MMP-9)
are known to promote cancer progression with their central role during
the invasion process as they degrade the connective tissue mainly com-
posed of type I collagen (or gelatine for denatured collagen) and theFig. 1. Effect of MG-BSA-AGEs and non-modiﬁed BSA on (A) the proliferation and (B) the vi
25–200 μg/ml MG-BSA-AGEs or non-modiﬁed BSA. Cell number (A) and cell viability (B) w
respectively. Control indicates non-treated cells. Results are presented as mean ± SD of three
(p b 0.05, p b 0.01 and p b 0.001), compared with the control.basement membrane mainly composed of type IV collagen [28]. AGE–
RAGE interactions also induce the activation of phosphoinositol-3 kinase
(PI3K) [27], oncogenic Ras, protein kinase C (PKC) and members of
Rho/GTPase (Cdc42 and Rac-1) signaling pathways, which lead to cell
survival, stress responses and apoptosis, release of growth factors and
pro-inﬂammatory cytokines, and motility with changes in cell shape,
respectively [29].
A meta-analysis study has reported that breast cancer rates are
increased by 23% for women who are diagnosed with type 2 diabetes
[30]. Breast cancer is a heterogeneous disease of particular interest. It
is classiﬁed into different subtypes based on expression of hormone
(oestrogen and progesterone) receptors and on its capability to invade,
which deﬁnes the degree of the malignancy. Much attention has been
devoted to the most aggressive phenotype of breast cancer with the
identiﬁcation of the roles of AGEs and the increase of RAGE expression
in patient's tissues [31]. However, biological effects of AGEs–RAGE on
breast cancer cells are poorly investigated. Here, in an attempt to under-
stand the biological effects of AGEs/RAGE in breast cancer, we investi-
gated the effects of methylglyoxal-derived bovine serum albuminability of breast cancer MDA-MB-231 cells. Cells were treated for 72 h of incubation with
ere determined using an automatic cell counter and the trypan blue exclusion method,
independent experiments. (*), (**) and (***) signify a statistically signiﬁcant difference
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breast cancer cell line MDA-MB-231, with regard to cell proliferation,
migration and invasion. The signaling pathways underlying the MG-
BSA-AGE-mediated effects were also investigated. To determine the
consequences of glycation onMDA-MB-231 cell functions, the biological
effects of non-modiﬁed BSA were also determined.
2. Materials and methods
2.1. Reagents
All reagents were obtained from Sigma-Aldrich (Dorset, UK) unless
mentioned otherwise.
2.2. Preparation of MG-BSA-AGEs
Bovine serum albumin (BSA) fraction V (10 mg/ml) was incubated
with 0.1 M methylglyoxal (MG) in 0.1 M sodium phosphate buffer con-
taining 3 mM sodium azide (pH 7.4) and left at 37 °C for 72 h. This
glycated BSA was dialyzed against distilled water to remove unbound
sugars. Dialysis was performed by stirring the samples at 4 °C with daily
changes of distilled water until equilibrium was reached. Non-modiﬁed
BSA underwent the same preparation conditions but in the absence of
MG. The resultingMG-BSA-AGEswere characterized using a ﬂuorescence
spectrophotometer (Luminescence spectrometer model LS 30 from
Perkin Elmer LAS Ltd., Buckinghamshire, UK) with emission at 420 nm
after excitation at 350 nm, which conﬁrmed the higher intensity of MG-
BSA-AGEs than that of non-modiﬁed BSA. Bacterial endotoxins were re-
moved from non-modiﬁed BSA and MG-BSA-AGE solutions using
detoxi-gel endotoxin-removing gel columns (Thermo Scientiﬁc, Rock-
ford, USA). Endotoxin levels in MG-BSA-AGEs and non-modiﬁed BSA
solutions were measured with an E-toxate kit based on the Limulus
Amebocyte lysate assay and were found to be below the detection
limit (b0.125 EU/ml). Protein concentrations were determined using aFig. 2. Effect ofMG-BSA-AGEs andnon-modiﬁedBSAon themigration of breast cancerMDA-M
cell migration measured from the wound edge (indicated by the arrow) after 24 h of incubation i
treated cells. Scale bar= 100 μm. (D) Quantiﬁcation of the number ofmigrated cells (black bars) a
conditions. Results are presented as mean ± SD of three independent experiments. (*) and (**) siBradford-based assay (Bio-Rad Laboratories, Hertfordshire, UK) with
BSA as a standard.
2.3. Culture of MDA-MB-231 breast cancer cells
MDA-MB-231 breast cancer cell line was obtained from American
Type Culture Collection (Manassas, VA, USA) and cultured in complete
medium composed of Dulbecco's modiﬁed Eagle's medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS),
2 mM glutamine and antibiotics (100 μg/ml streptomycin, 100 IU/ml
penicillin) at 37 °C in a saturated air humidity/5% CO2 incubator.
2.4. Cell proliferation assay
MDA-MB-231 cells (2.5 × 104/ml) were seeded in complete medium
in 24-well plates (Nunc™, Fisher Scientiﬁc, Loughborough, UK). After
4 h of incubation to allow the cells to attach to the bottom of the well,
themediumwas changed to a serum-poormedium (SPM) supplemented
with 2.5% FBS in the presence or absence of different concentrations (25–
200 μg/ml) of MG-BSA-AGEs or non-modiﬁed BSA. Each condition was
performed in triplicate. After 72 h of incubation, the cells were detached
in 250 μl of 0.05% trypsin/0.02% EDTA, and each cell suspensionwas dilut-
ed in 10 ml of isotonic solution and counted using a Beckman-Coulter
counter (Buckinghamshire, UK). Cell viability was assessed using the
trypan blue exclusion method, which stains dead cells; whereas viable
cells actively exclude the dye. The percentage of cell viability was deter-
mined according to the following formula: % viability= (viable unstained
cells)/(viable unstained cells + dead stained cells) × 100.
2.5. Cell migration assay
MDA-MB-231 cells (5 × 104/ml) were seeded in complete medium
on Thermanox® plastic coverslips (Nunc™) in 24-well plates. After
24 h of incubation, the cells reached pre-conﬂuence on the coverslips;B-231 cells.Representative photomicrographs (×400magniﬁcation) showingMDA-MB-231
n (A) non-treated (control) or (B) 50 μg/ml MG-BSA-AGE-treated or (C) non-modiﬁed BSA-
nd the distance of migration (gray bars) of MDA-MB-231 cells treated in the aforementioned
gnify a statistically signiﬁcant difference (p b 0.05 and p b 0.01), compared with the control.
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At conﬂuence, cells were washed three times with sterile PBS, and each
monolayer was wounded on two sides with a sterile razor blade,
which formed two wound edges per coverslip with cell denuded
areas. Dislodged cells and cell debris were removed with sterile PBS.
The coverslips with wounded cell monolayers were returned to the
well containing SPM with or without different concentrations of MG-
BSA-AGEs and non-modiﬁed BSA for 24 h of incubation. Each condition
was performed in duplicate. At the end of the experiment, the cellswere
rinsed with PBS, ﬁxed with 100% ethanol for 5 min and then left to dry
at room temperature. The cells were stained with 0.1% methylene blue
for 2 min and washed abundantly with distilled water to reveal the
degree of wound recovery. Four pictures from the wound edge of each
side were taken to assess the cell migration by counting the number
of themigrated cells and bymeasuring the distance of the cellmigration
using image J software (http://rsbweb.nih.gov/ij/index.html).
2.6. Cell invasion Matrigel™ assay
Growth-factor reduced Matrigel™ (Becton Dickinson, Oxford, UK)
was diluted (1:6) in serum-free medium then poured onto the porous
membrane of a Transwell® 24-insert plate (Nunc™). The plate was
incubated for 30 min to allow the gel to polymerise. MDA-MB-231
cells were seeded at 104 cells/100 μl in SPM (in the upper chamber of
the Transwell®) in the presence or absence of different concentrations
of MG-BSA-AGEs or non-modiﬁed BSA (in the well corresponding to
the lower chamber of the Transwell®). Each condition was performedFig. 3. Effect of MG-BSA-AGEs and non-modiﬁed BSA on the invasion of breast cancer MDA
MDA-MB-231 cells (control), (B) cells treatedwith 100 μg/mlMG-BSA-AGEs and (C) non-modiﬁ
(a reconstituted basementmembrane) andmigrated across the porousmembranewere stained
after treatmentwith 25–200 μg/mlMG-BSA-AGEs or non-modiﬁed BSA, comparedwith the con
statistically signiﬁcant difference (p b 0.01), compared with the control.in duplicate. After 24 h of incubation, the non-migrated cells on the
upper side of the porous membrane were removed using a cotton swab
soaked with PBS. The cells that migrated across the porous membrane
were ﬁxedwith 4% paraformaldehyde and then stainedwith 0.1% Giemsa
stain for cell counting using a Zeiss optical microscope.2.7. Gelatine zymography
Matrix metalloproteinase (MMP) activities in the cell-culture media
that had been used for the cell invasion assay (as aforementioned) were
measured. The medium was collected and centrifuged (600g for 15 min
at 4 °C). Protein concentrationwas determinedusing the Bradford protein
assay (Bio-Rad), and the samples (100 μg of protein) weremixedwith an
equal volume of non-reducing sample buffer. The samples were incubat-
ed at room temperature for 10 min, after which they were subjected
to electrophoresis on 7.5% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) containing 1 mg/ml gelatine as a substrate.
The gels were washed in re-naturation buffer (2.5% Triton X-100) for
30 min at room temperature to remove SDS and to re-nature the MMPs
in the gels. The gels were then rinsed in activation buffer (50 mM
Tris–HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02% Brij 35) for 30 min to
activate the MMPs. Gels were incubated overnight at 37 °C with fresh
activation buffer and stained with 0.5% Coomassie blue R-250 for 2 h
at room temperature. After destaining the gels, MMP gelatinase activity
was detected as a white band on a dark background and quantiﬁed by
densitometry using Image J software.-MB-231 cells. Representative photomicrographs (×100 magniﬁcation) of (A) untreated
ed BSA in theMatrigel™ invasion assay. Stimulated cellswhich had invaded theMatrigel™
withGiemsa dye for counting. (D)Quantiﬁcation of number of invadedMDA-MB-231 cells
trol. Results are presented asmean± SD of three independent experiments. (**) signiﬁes a
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MDA-MB-231 cells (6 × 105/2 ml) were seeded in complete medium
in six-well plates (Nunc™). After 48 h of incubation, the medium was
renewed with SPM for a further 24-h incubation, and MG-BSA-AGEs or
non-modiﬁed BSA was added for 5, 10, 30 and 120 min of incubation.
After washing in cold PBS, all the intracellular proteins were extracted
after lysing the cells with 120 μl/well of ice-cold radioimmunopre-
cipitation buffer (pH 7.5) containing 25 mM Tris–HCl, 150 mM NaCl,
0.5% sodium deoxycholate, 0.5% SDS, 1 mM EDTA, 1 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF), 1%
Triton X-100 and 1 μM leupeptin.
For a time-course study of RAGE expression, the cells were treated
with or without MG-BSA-AGEs or non-modiﬁed BSA for 10 min and
24–72 h of incubation. The cells were then lysed with 80 μl/well of ice-
cold buffer containing 10 mM Tris–HCl (pH 7.4), 50 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 0.05% SDS, 50 mM sodium ﬂuoride, 100 μM sodi-
um orthovanadate, 10 mM beta-glycerophosphate, 10 mM sodium pyro-
phosphate, 100 μg/ml PMSF, 3 mM benzamidine, 1 mM dithiothreitol,
10 μM leupeptin, 5 μM pepstatin A and a cocktail of protease inhibitors.
Protein lysates (100 μg) were mixed with 2× Laemmli sample buffer,
denatured by boiling in a water bath for 15 min and then centrifuged.
To remove the cell debris, the cell lysateswere centrifuged at 20,000g
for 30 min at 4 °C. The amount of proteins for each sample was deter-
mined by Bio-Rad protein assay andwas ﬁxed at 20–50 μg for equal pro-
tein loading. An equal volume of protein samples and 2× sample buffer
were mixed in Eppendorf® tubes and then placed in the boiling water
for 15 min. Samples were separated along with pre-stained molecular
weight markers by 12% SDS-PAGE. Proteins were electroblotted onto
nitrocellulose membranes and the membranes were blocked for 1 h
at room temperature in Tris-buffered saline (TBS)-Tween (pH 7.4) con-
taining 1% BSA. Membranes were stained with the following primary
antibodies diluted in the blocking buffer, overnight at 4 °C on a rotating
shaker: mouse monoclonal antibodies to phospho-extracellular signal-Fig. 4. Effect of MG-BSA-AGEs on MMP-9 and MMP-2 activities produced by breast cancer
zymograhic analysis showing the activity of MMP-9 and MMP-2 from cell conditioned media
MG-BSA-AGEs, compared with untreated cell-condition medium (control, c). The gels revea
gelatinolytic activity of pro- and active MMP-9 and (C) pro-MMP-2 expressed as relative activ
four independent experiments. (*), (**) and (***) signify a statistically signiﬁcant difference (pregulated kinase (p-ERK1/2, Tyr204 of ERK1, sc-7976; 1:1000 dilution),
rabbit polyclonal antibodies to total ERK1/2 [C-16] (t-ERK1/2, sc-93;
1:1000 dilution) and mouse monoclonal antibodies to RAGE [E-1] (sc-
74473; 1:1000 dilution) provided by Santa Cruz Biotechnology (Heidel-
berg, Germany) and mouse monoclonal antibodies to GAPDH [6C5]
(ab8245; 1:2000 dilution) and to p70S6K1 [6B2] (ab119252; 1:1000)
and rabbit monoclonal antibodies to phospho-p70S6K1 (p-p70S6K1,
Tyr412, ab78413; 1:1000) by Abcam (Cambridge, UK). After washing
ﬁve times for 10min in TBS-Tween at room temperature, themembranes
were stained with either rabbit anti-mouse or goat anti-rabbit
horseradish peroxidase-conjugated secondary antibodies diluted
in TBS-Tween containing 5% de-fatted milk (1:1000 dilution) for
1 h at room temperature with continuous mixing. After a further ﬁve
washes in TBS-Tween, proteins were visualized using ECL chemilumi-
nescent detection (Amersham Biosciences, Buckinghamshire, UK) and
analyzed using GeneSnap software with Gene tool image analyser
(Syngene, Cambridge, UK).
2.9. RNA extraction and real-time RT-PCR
MDA-MB-231 cells (6 × 105/2ml)were seeded in completemedium
in six-well plates. After 4 h of incubation, themediumwas renewedwith
SPM in the presence or absence of 100 μg/mlMG-BSA-AGEs for 24–72 h
of incubation. Whole RNA extraction was performed using the RNeasy
mini Kit (Qiagen Inc., Valencia, CA) in order to quantitatively monitor
by real-time PCR themRNA expression of human Rage (accession num-
ber AB036432) related to internal control house-keeping gene glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH, accession number
DQ403057). Complementary DNA (cDNA) was produced from total
RNA extracts via reverse transcription using Transcriptor ﬁrst-strand
cDNA synthesis kit (Roche Molecular Systems, Pleasanton, CA), and
the reaction was carried out in Tetrad2 Thermal Cycler (Bio-Rad). The
primer pair sequences used from Invitrogen (Life technologies, Paisley,
UK) were: 5′-GGC TGG TGT TCC CAA TAA GG-3′ and 3′-TCA CAG GTCMDA-MB-231 cells during the Matrigel™ invasion assay. (A) Representative gelatine
collected after Matrigel invasion assay by MDA-MB-231 cells treated with 25–100 μg/ml
led gelatinolytic activities of pro- and active MMP-9 and pro-MMP-2. (B) Quantitative
ity, which was calculated as a ratio of the control. Results are presented as mean ± SD of
b 0.05, p b 0.01 and p b 0.001), compared with the control.
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5′-TGA TGA CAT CAA GAA GGT GAA G-3′ and 3′-TCC TTG GAG GCC ATG
TGG GCC AT-5′ for human GAPDH as designed using the primer3 soft-
ware. The real-time PCR was performed using a QuantiTect Reverse
Transcription kit containing PCR SyberGreen Master Mix (Applied
Biosystems, Grand Island, NY) and performed on 7500 real-time PCR
system (Applied Biosystems). For each analysis, a negative control
was prepared using all the reagents except the cDNA template.
All the reactions were run in triplicate, and the fold-change of ex-
pression was calculated according to delta delta Ct (ΔΔCt) method
as follows: fold-change = 2(−ΔΔCt) with ΔΔCt = ΔCt (RAGEtreated−
GAPDHtreated)− ΔCt (RAGEcontrol− GAPDHcontrol).
2.10. Flow cytometry analysis
MDA-MB-231 cells (6 × 105/2 ml) were seeded in complete medium
in six-well plates. After 48h of incubation, themediumwas renewedwith
SPM for a further 24-h incubation, and then 100 μg/ml MG-BSA-AGEs or
non-modiﬁed BSA were added for a 10-min incubation. Each condition
was performed in triplicate. The cellswerewashedwith PBS then scraped
to maintain intact the structure of the transmembrane RAGE protein.
After centrifugation (300g for 10 min), 106 cells were re-suspended in
20 μl of PBS then 20 μg/ml of mouse anti-RAGE (E-1) antibody or 2 μg
of mouse IgG1 isotype control (ab91353 from Abcam) were added. The
mixture was then kept on ice for 45 min. The excess antibody was re-
moved by washing the cells twice with PBS followed by centrifugation.
After the second centrifugation, the cells were re-suspended in 20 μl of
PBS, and 20 μg/ml of monoclonal anti-mouse antibody-FITC (Invitrogen,
Paisley, UK) were added. The mixture was then kept on ice for 30 min.
The RAGE expression level was measured using FACScan analysis soft-
ware from FACSCalibur Flow Cytometer (Becton Dickinson).
2.11. Kinexus phospho-protein array analysis
MDA-MB-231 cells (6 × 105/2 ml) were seeded in complete medium
in six-well plates. After 48 h of incubation, the medium was changed to
SPM. After a further 24-h incubation, 100 μg/ml MG-BSA-AGEs or non-
modiﬁed BSA were added, and the cells which were then incubated for
10 min at 37 °C. To determine the protein expression proﬁle of signaling
pathways downstream of RAGE, a phospho-protein array analysis
(Kinetworks PhosphoSite Screen, KPSS-1.3) was performed by
Kinexus Bioinformatics (Vancouver, Canada). Protein samples (500 μg)
from MG-BSA-AGE- or non-modiﬁed BSA-treated and untreated cells
were extracted according to the manufacturer's instructions. The
samples were used for a multi-immunoblotting assay based on
SDS-polyacrylamide mini-gel electrophoresis with 20-lane multi-
immunoblotters using different primary antibodies. Most of the multi-
immunoblotting assays were performed at least twice. Protein expres-
sions were visualized by chemiluminescence and relative expression
was determined by Kinexus and expressed in counts per minute.
2.12. RAGE neutralization
To investigate whether MG-BSA-AGEs act through RAGE, the cells
were treated with an anti-RAGE antibody to neutralize all the RAGE
receptors. Brieﬂy, MDA-MB-231 cells were seeded in complete mediumFig. 5. Effect ofMG-BSA-AGEs on the phosphorylation of signaling proteins inMDA-MB-231 ce
induced by 100 μg/mlMG-BSA-AGEs after different incubation times varying from5 to 120min, co
the effect of 100 μg/ml MG-BSA-AGEs or non-modiﬁed BSA on the phosphorylation of ERK1/2 exp
ratio to the total ERK1/2 (t-ERK1/2), the loading control. Results are presented as mean ± SD of
comparedwith the control. (C)Multi-immunoblotting of 35 phospho-proteins expressed in untre
with non-modiﬁed BSA (C3) after 10 min of incubation. (C4) The bar graph shows the relative exp
ratio to the untreated cells (control).in 24-well plates according to the protocols of upstream applications
previously described. The medium was renewed with SPM, and then
20 μg/ml mouse monoclonal anti-RAGE [E-1] antibody or 20 μg/ml
IgG1, which was used as an isotype control, was added. After 1 h of
incubation, the cells were treated with 100 μg/ml MG-BSA-AGEs for
10 min or a 24–72-h stimulation at 37 °C followed by RNA or protein
extraction for real-time RT-PCR and Western blotting. The cells were
also eventually subjected to all functional cell-based assays mentioned
previously. Each condition was performed in triplicate, and each exper-
iment was repeated three times.
2.13. Statistical analysis
Results are expressed as the mean ± standard deviation (SD).
Experimental pointswere gathered for aminimumof three independent
experiments. An unpaired Student's t-testwas used for the comparison of
two groups. A value of P b 0.05 was considered signiﬁcant.
3. Results
3.1. MG-BSA-AGEs increase MDA-MB-231 cell proliferation
Weﬁrst evaluated the effects of increasing concentrations ofMG-BSA-
AGEs and non-modiﬁed BSA varying between 25 μg/ml and 200 μg/ml on
MDA-MB-231 cell proliferation (see Section 2). We found that MG-BSA-
AGEs affected cell number, in a dose-dependent manner, increasing
then decreasing cell proliferation as a bell-shaped curve. A peak of stimu-
lation (2.0-fold increase, p b 0.01) was attained in the presence of 50 and
100 μg/mlMG-BSA-AGEs, whereas the highest concentration (200 μg/ml)
did not alter the cell growth compared with the untreated cells used as
control (Fig. 1A). To estimate the speciﬁc effect of MG-BSA-AGEs on cell
proliferation, non-modiﬁed BSA was also tested. Compared with the
control, only a low concentration of BSA (50 μg/ml) slightly increased
cell proliferation (1.25-fold, p b 0.05) whereas no effect was observed
with other concentrations (Fig. 1A). Furthermore, for each condition,
the percentage cell viability was assessed by trypan blue exclusion and
revealed a high cell viability between 97% and 85% from the control
to the highest concentration of MG-BSA-AGEs or non-modiﬁed BSA
(Fig. 1B).
3.2. MG-BSA-AGEs increase MDA-MB-231 cell migration
To assess the effect of MG-BSA-AGEs on the migration of the breast
cancer cell line MDA-MB-231, the cells were subjected to the wound-
healing assay followed by a 24-h treatment in SPM (which reduced
the cell growth) with different concentrations (25–200 μg/ml) of MG-
BSA-AGEs or non-modiﬁed BSA (Fig. 2). Representative photomicro-
graphs of cell migration in untreated condition used as control
(Fig. 2A), or treated conditions either with 50 μg/ml MG-BSA-AGEs
(Fig. 2B) or non-modiﬁed BSA (Fig. 2C) are shown. Compared with the
control (Fig. 2A and D) and to non-modiﬁed BSA (Fig. 2C and D), MG-
BSA-AGEs at concentrations of 25–100 μg/ml increased the number of
migrated cells (2.0-fold, p b 0.05, Fig. 2D). MG-BSA-AGEs signiﬁcantly
increased the distance of cell migration in a dose-dependent manner
with a peak at 50 μg/ml (2.0-fold increase, p b 0.01), compared with
the control (Fig. 2D). No change in cell migration was observed withlls. (A) RepresentativeWestern blot analysis showing phosphorylation of ERK1/2 (p-ERK1/2)
mparedwith untreated cells (control). (B) RepresentativeWestern blot analysis (B1) showing
ression, compared with the control. (B2) Relative phosphorylation of ERK1/2 calculated as a
three independent experiments. (**) signiﬁes a statistically signiﬁcant difference (p b 0.01),
ated (C1) MDA-MB-231 cells, cells treatedwith 100 μg/mlMG-BSA-AGEs (C2) or cells treated
ression of the relevant phospho-proteins expressed in counts per minute and calculated as a
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modiﬁed BSA had no effect on MDA-MB-231 cell migration at most
concentrations, treatment with the highest concentration (200 μg/ml)
resulted in a signiﬁcant inhibition (40% decrease, p b 0.05) in the
distance migrated as compared with the control (Fig. 2D).
3.3. MG-BSA-AGEs increase MDA-MB-231 cell invasion
The invasion of the basement membrane is a critical step during
tumor progression because the basement membrane represents the
last barrier for the cancer cells to reach the circulatory system and to
be disseminated via metastasis. The effect of MG-BSA-AGEs on the
MDA-MB-231 cell invasion was estimated by counting the stained
migrated cells that passed across the porous membrane after invading
theMatrigel™, a reconstituted basement membrane (Fig. 3). Represen-
tative photomicrographs of cell invasion in untreated condition consid-
ered as control (Fig. 3A) or treated either with MG-BSA-AGEs (Fig. 3B)
or non-modiﬁed BSA (Figs. 3C) are shown. Compared with the control
(Fig. 3A), MG-BSA-AGEs at 50 μg/ml and 100 μg/ml (Fig. 3C) signiﬁcant-
ly increasedMDA-MB-231 cell invasion (2.0-fold, p b 0.01) (Fig. 3D). By
contrast, MG-BSA-AGEs at 25 μg/ml and 200 μg/ml did not induce any
signiﬁcant changes in cell invasion, compared with the control. At all
concentrations used, no effect of non-modiﬁed BSA on MDA-MB-231
cell invasion was observed, compared with the control (Fig. 3D).
3.4. MG-BSA-AGEs enhance MMP-9 activity
Matrix metalloproteinases (MMP)-2 and MMP-9, also called
gelatinases, play a central role in the degradation of the type IV col-
lagen of the basement membrane, thus contributing to tumor invasion
and metastasis. Compared with the MMP-9 activity in untreated MDA-
MB-231 cell-condition medium (control) as assessed by gelatine sub-
strate zymography, treatmentwith 50 and 100 μg/mlMG-BSA-AGEs sig-
niﬁcantly (p b 0.01) enhanced MMP-9 activity (1.5-fold and 2.1-fold,
respectively, Fig. 4A and B). A decrease in the activity of pro-MMP-9,
which is the precursor and inactive form of MMP-9, was noticed when
the cells were treated with 200 μg/ml MG-BSA-AGEs, compared with
the control (Fig. 4A and B). The activity of pro-MMP-2 was enhanced
after treatmentwithMG-BSA-AGEs at all concentrations used; however,
no active MMP-2 was observed (Fig. 4).
3.5. MG-BSA-AGEs increase the phosphorylation of signaling proteins
To optimize incubation time corresponding to themaximal cell signal-
ing induced by 100 μg/ml MG-BSA-AGEs (concentration previously
shown to signiﬁcantly increase all MDA-MB-231 cell functions), Western
blotting was used to determine the expression levels of phospho-ERK1/2
(p-ERK1/2) in MDA-MB-231 cells treated with MG-BSA-AGEs for 5, 10,
30 and 120 min (Fig. 5). MG-BSA-AGEs increased the phosphorylation
of ERK1/2 in cells after 5 min of incubation (Fig. 5). The maximum p-
ERK1/2 expression level was reached at the 10-min incubation point.
Expression levels of p-ERK1/2 slightly decreased after 30 min of incuba-
tion and nearly disappeared at 120-min incubation point (Fig. 5A). To
conﬁrm the effect of MG-BSA-AGEs on p-ERK1/2 expression level, MDA-
MB-231 cells were treated with or without 100 μg/ml MG-BSA-AGEs or
non-modiﬁed BSA for 10 min (Fig. 5B). Compared with untreated cells
(control), MG-BSA-AGE treatment increased the phosphorylation of
ERK1/2 (1.8- and 2.8-fold increase for p-ERK1 and p-ERK2, respectively)
while no change of ERK1/2 phosphorylation was observed in non-
modiﬁed BSA-treated cells (Fig. 5B).
Awider investigation of the downstreamphosphorylated proteins of
MG-BSA-AGEs/RAGE signaling pathways was proceeded as follows: the
whole cell lysates of untreated MDA-MB-231 cells (control, Fig. 5C1) or
cells treated with 100 μg/ml MG-BSA-AGEs (Fig. 5C2) and 100 μg/ml
non-modiﬁed BSA (Fig. 5C3) were analyzed using the phospho-protein
array analysis KPSS-1.3 for 35 phospho-proteins including p-ERK2(Fig. 5C). Like using Western blot analysis, quantiﬁcation of the
immuno-blots showed that MG-BSA-AGEs also resulted in a 3.0-fold
increase of ERK2 phosphorylation, which reinforced the reproducibility
and the validity of the data (Fig. 5B). MG-BSA-AGEs increased the phos-
phorylation of the ribosomal protein serine S6 kinase (p70S6K)-beta 1
(25.4-fold increase), the signal transducer and activator of transcription
(STAT)-3 (8.0-fold increase), MAPK p38 and glycogene synthase-serine
kinase (GSK)-3α (5.6-fold and 3.2-fold, respectively), and MAPK/ERK
protein-serine kinase 1/2 (MKK1/2, 4.6-fold increase), compared with
untreated cells (Fig. 5C4). Furthermore, the phosphorylation of c-Jun
and its kinase JNK was increased (2.0-fold) in MG-BSA-AGE-treated
cells as compared with untreated cells (control). The phosphorylation
of the tumor-suppressor protein retinoblastoma-associated protein-1
(pRb) was also increased (2.6-fold) in MG-BSA-AGE-treated cells. Cell
treatment with 100 μg/ml non-modiﬁed BSA had no signiﬁcant effects
on the phosphorylation of the proteins studied, comparedwith the con-
trol (Fig. 5C).3.6. MG-BSA-AGEs up-regulate RAGE expression
A time-course of expression levels of RAGE in MDA-MB-231 cells
following treatment with 100 μg/ml MG-BSA-AGEs was established
usingWestern blotting and real-time RT-PCR. MG-BSA-AGEs treatment
led to up-regulation of RAGE protein levels in a time-dependentmanner
(Fig. 6A). Within 10 min, RAGE expression levels increased in MG-BSA-
AGE-treated cells, compared with the basal level of RAGE expressed
in untreated cells (Fig. 6A). These data were further conﬁrmed using
ﬂow cytometry analysis (Fig. 6B). Western blot analysis revealed a
peak of RAGE protein expression levels (3.0-fold increase, p b 0.0001)
after 24 h of incubation with MG-BSA-AGEs, whereas a peak of RAGE
mRNA expression (5.0-fold increase, p b 0.001) was noticed after
48 h of incubation (Fig. 6C). After 72 h of incubation with MG-BSA-
AGEs, there was not signiﬁcant difference in RAGE transcript and
protein levels between MG-BSA-AGEs treated and untreated cells
(Fig. 6).3.7. MG-BSA-AGEs stimulate MDA-MB-231 cells through RAGE
To check whether MG-BSA-AGEs stimulated MDA-MB-231 cells
through their major receptor RAGE, the cells were pre-treated with
either a neutralizing RAGE antibody to block all the RAGE receptors or
with an isotype control IgG1 used as a negative control (Fig. 7). RAGE
neutralization process was applied to verify whether MG-BSA-AGEs
induce the increased phosphorylation of signaling proteins such as
ERK1/2 (the key protein of signaling pathways) and p70S6K1 (the most
over-phosphorylated protein induced by MG-BSA-AGEs) through RAGE.
The isotype control IgG1 did not affect ERK1/2 phosphorylation induced
by MG-BSA-AGEs, compared with the basal expression level of p-ERK1/
2 in untreated cells used as control (Fig. 7A). However, 100 μg/ml BSA-
AGEs did not enhance ERK1/2 phosphorylation in the cells pre-treated
with neutralizing RAGE antibody (Fig. 7A). In addition, the protein array
analysis previously described was conﬁrmed by a similar concomitant
increase of p70S6K1 phosphorylation induced by MG-BSA-AGEs even in
IgG1-treated cells, compared with the control (Fig. 7B). The blockade of
RAGE completely inhibitedMG-BSA-AGE-inducedp70S6K1phosphoryla-
tion (Fig. 7B). On the cell function aspects, the addition of MG-BSA-AGEs
to IgG1-pretreated cells induced a signiﬁcant increase in cell proliferation
(1.8-fold, p b 0.001, Fig. 7C), cell migration (2.0-fold, p b 0.05, Fig. 7D) and
cell invasion (1.6-fold, p b 0.05, Fig. 7E) as compared with the untreated
cells (control). However, the addition of MG-BSA-AGEs to cells pre-
treated with anti-RAGE antibody did not change the cellular processes
as comparedwith the control. Altogether,MG-BSA-AGEs lost their biolog-
ical effects after the blockade of RAGE, demonstrating that MG-BSA-AGEs
act through RAGE.
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Diabetes and cancer are a cause for concern because of the high inci-
dence of these diseases in Western countries and, more recently, inFig. 6. Time-course of RAGEprotein andmRNA expression in breast cancerMDA-MB-231 cel
effect of 100 μg/mlMG-BSA-AGEs on RAGE expression inMDA-MB-231 cells after incubation for
the relative expression of RAGE calculated as a ratio to GAPDH expression, the loading control. (
BSA-AGEs after 10 min of incubation. IgG1 was used as an isotype control. Bar graph (B2) ind
isotype control. (C) Relative expression of RAGE mRNA as determined using real-time PCR a
(**) signify a statistically signiﬁcant difference (p b 0.05 and p b 0.01), compared with the condeveloping countries. A growing body of epidemiological evidence sug-
gests amolecular link between diabetes and breast cancer [31,32]. In di-
abetic patients, the most circulating and abundant advanced glycation
endproducts (AGEs)-derived protein is serum glycated albumin [33].ls treatedwithMG-BSA-AGEs. (A) RepresentativeWestern blot analysis (A1) showing the
10min or 24, 48 or 72 h, comparedwith untreated cells (control). Bar graph (A2) showing
B) Representative FACS analysis (B1) of the RAGE up-regulation induced by 100 μg/mlMG-
icating the quantiﬁcation of the percentage of RAGE-positive cells calculated as a ratio to
nalysis. Results are presented as mean ± SD of three independent experiments. (*) and
trol.
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higher than in healthy controls [32]. To date, the biological effects of
glycated albumin on human breast cancer cells have been poorly
described.
Here,we have shown thatMG-BSA-derived AGEs increase the prolif-
eration, migration and invasion (associated with an enhancement
of MMP-9 gelatinase activity) of the invasive and non-hormone-
dependent cell line MDA-MB-231 in vitro. Furthermore, MG-BSA-AGEs
increase expression of RAGE and phosphorylation of ERK1/2 and other
key signaling proteins such as p70S6K1. In addition, the blockade of
RAGE using a neutralizing RAGE antibody removes all these MG-BSA-
AGE effects. By contrast, non-modiﬁed BSA showed little biological ef-
fects on MDA-MB-231 cells. These new ﬁndings suggest that AGEs
might contribute to the development and progression of invasive breastFig. 7. RAGEmediates the effects ofMG-BSA-AGEs in breast cancerMDA-MB-231 cells. Repre
of (A) ERK1/2 and (B) p70S6K1 after the blockade of RAGE by an anti-RAGE antibody, compare
expression levels of (A2) p-ERK1/2 and (B2) p-p70S6K1 calculated as a ratio to the total ERK1/
BSA-AGE-induced (C) cell proliferation, (D)migration and (E) invasion after RAGE blockade usin
an isotype control IgG1. Results are presented as mean± SD of three independent experiment
with the control.cancer. RAGE over-expression and the phosphorylation of key proteins
induced by AGEs might represent promising targets for drug therapy
to treat diabetic patients with breast cancer.
MG-BSA-AGEs increased MDA-MB-231 cell proliferation, migration
and invasion, in a dose-dependent manner as shown by a bell-shaped
curve, while non-modiﬁed BSA had no biological effects, except a slight
stimulatory effect on cell proliferation at 50 μg/ml and an inhibitory
effect on cell migration at 200 μg/ml. This slight pro-mitogenic effect
of non-modiﬁed BSA is correlated with the induction of ERK1/2 phos-
phorylation observed at short incubation time (10 min) at the same
concentration (50 μg/ml) in our pilot studies (data not shown),whereas
no increase in phosphorylation of ERK1/2 was induced by 100 μg/ml of
non-modiﬁed BSA. The pro-mitogenic effect of native BSA was also re-
ported by Chung and colleagues using tubular epithelial cells in similarsentativeWestern blot analysis showing the loss ofMG-BSA-AGE-induced phosphorylation
d with untreated cells (control) and an isotype control IgG1. Bar graphs show the relative
2 (t-ERK1/2) and total p70S6K1 (t-p70S6K1), the respective loading controls. Loss of MG-
g a neutralizingblocking anti-RAGEantibody, comparedwith untreated cells (control) and
s. (*) and (**) signify a statistically signiﬁcant difference (p b 0.05 and p b 0.01), compared
Fig. 7 (continued).
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able amount of AGEs reported to be observed in native albumin, the
most common serum protein known to be readily glycated in vivo. In-
deed, native albumin is modiﬁed by 0.3 mol/mol of sugars and this is
likely to be by glucose, the major metabolic sugar [35]. However, mod-
iﬁcation by other sugars such as methylglyoxal cannot be ruled out and
may contribute towards AGE formation on native albumin. In contrast,
the inhibitory effect of high concentration of native BSA on cell migra-
tionmay be caused by the inhibition of cell adhesion, which plays a crit-
ical role in cell motility, due to the high adsorption of BSA between the
culturemedium and the solid surface as it was previously reported [36].
Here, bell-shaped curves representing the MDA-MB-231 cell response
to MG-BSA-AGE biological effects are indicative of a bivalent bridging
mechanism describing the dimerization/oligomerization of speciﬁc
cell-surface receptors after binding with the ligand [37]. Indeed,
throughout this present study, the maximal cell response was obtained
with 50 and 100 μg/ml MG-BSA-AGEs, which might correspond to the
optimal oligomerization of the AGE receptor such as RAGE to induce
the maximal signaling. Therefore, the loss of the cell response seen at
the highest concentration (i.e. 200 μg/ml) of MG-BSA-AGEs may be
due to impediment of RAGE oligomerization. Furthermore, using an
epitope-deﬁned monoclonal antibody that speciﬁcally recognizes re-
ceptor oligomerization, Xu and colleagues demonstrated the impor-
tance of RAGE oligomerization for the formation of active signaling
complexes [38]. In addition, a recent study provides insights into the
factors that inﬂuence AGEs–RAGE binding including glycation agent
like methylglyoxal and the RAGE structure [39]. Indurthi et al. [39]
used 1 and 5mMmethylglyoxal tomodify BSA respectively; they demon-
strated that higher concentration of methylglyoxal produced more AGEs,
which showed increased binding afﬁnity to RAGE. They suggested thathigher glycation generate more potential binding sites for RAGE in
the protein surface [39]. In the present study, we applied 100 mM
methylglyoxal to generateMG-BSA-AGEs to ensure a high binding poten-
tial to RAGE. Using siRNA technology, RAGE has been shown to play a
critical role in the growth of human breast cancer cell lines, including
MDA-MB-231 [21]. Most studies on BSA-AGEs, including this investiga-
tion, compare the biological effects of MG-BSA-AGEs with native non-
modiﬁed BSA, which in agreement with previous work show no biologi-
cal effects or little effects at the concentrations or experimental conditions
used [40]. Indeed, native globular BSA even bound to the cell surface rare-
ly triggers speciﬁc transduction signaling unlike BSA-AGEs [41,42]. There-
fore, the mode of action of MG-BSA-AGEs is dependent on pathways
mediated via RAGE rather than BSA-mediated pathways.
In this present study, we also showed that the enhancement of
MDA-MB-231 cell invasive capacity induced by MG-BSA-AGEs was as-
sociated with MMP-9 gelatinase activity without changing MMP-2
gelatinase activity. Non-modiﬁed BSA had no effect on bothMMP activ-
ities. Invasion andmetastasis are key cell events resulting in tumor pro-
gression and are the hallmarks of cancermalignancy. Duringmetastasis,
cancer cells degrade the matrix by production and secretion of MMPs.
MMPs facilitate cell migration and invasion across the connective tissue
and the basementmembrane to reach the blood circulationwhich is the
main route of tumor dissemination towards vascularized organs. A
study has shown that incubating human lung adenocarcinoma cell
with glyceraldehyde-AGEs for 48 h, promoted cell migration and inva-
sion across Matrigel™ with enhancement of MMP-2 activity but not
MMP-2 mRNA [43]. Recently, Noh and colleagues reported MMP-2
from body ﬂuid as a putative biomarker in metastatic breast cancer
[44]. However, Hallett and colleagues targeted MMP-9 mRNA in a
mouse model using anti-MMP-9 DNAzyme transfected into MDA-MB-
231 cells, and they reported a decrease of breast cancer and conﬁrmed
the key role of MMP-9 in breast cancer metastasis [45]. Furthermore,
using a murine macrophage cell line, it has been shown that AGEs
have regulated MMP-9 production via RAGE, which is in agreement
with our present work, and was associated with activation of ERK1/2,
p38 MAPK and NF-κB [46]. Therefore, our results suggest that MG-
BSA-AGEs might promote breast tumor progression by increasing can-
cer cell migration, invasion and MMP-9 activity.
During MDA-MB-231 cell treatment with MG-BSA-AGEs, the cells
displayed a maximum RAGE up-regulation after 24 h of incubation.
Recently, Shi and colleagues reported that AGEs up-regulate RAGE
expression in various tissues, reaching amaximumafter a 24-h treatment,
which facilitates the AGE–RAGE response by forming a positive feedback
loop [41]. This suggests that RAGE up-regulation induced by MG-BSA-
AGEsmay contribute to the increased cellular response assessed as prolif-
eration, migration and invasion. In addition, in endothelial progenitor
cells, BSA-AGE-induced RAGE up-regulation has been demonstrated to
be ERK1/2 and p38 MAPK-dependent but not mediated by JNK MAPK
[47]. We observed the peak up-regulation of RAGE mRNA expression
level after 48 h of treatmentwithMG-BSA-AGEs, whereas the protein ex-
pression levelwas lower, indicating a negative-feedback loop of the trans-
lational regulatory system of RAGE protein expression. To conﬁrm this
hypothesis, additional studies might be of interest on the key factors
regulating the translational system of RAGE protein expression such as,
microRNA and nuclear transcription factors p65/50 NF-κB and Sp-1/
ERα, previously demonstrated to be involved in this regulatory process
[48].
p-ERK1/2 is a phospho-protein widely known to play a central role
in most cellular responses including cell proliferation, migration and
invasion. We found that the optimal signal for MG-BSA-AGE-induced
p-ERK1/2 expression in MDA-MB-231 cell line was obtained after 10-
min treatment. Similar early phosphorylation of ERK1/2 was reported
to be induced by BSA-AGEs in various cell types [34]. We demonstrated
that MG-BSA-AGEs enhanced phosphorylation of ERK1/2 and stimulat-
ed all cellular functions through RAGE, as these processes were attenu-
ated after neutralization of the receptor using a speciﬁc monoclonal
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receptors such as CD36, scavenger receptors class A type II, class B
type I and AGE receptors 1, 2 and 3, which are mainly implicated in
the detoxiﬁcation of AGEs rather than in signaling processes [49].
Although 100 μg/ml non-modiﬁed BSA did not change the phospho-
proteomeproﬁle ofMDA-MB-231 cells compared to untreated cells, at a
similar concentration, MG-BSA-AGEs concomitantly increased the
phosphorylation of p70S6K1, STAT-3, p38 MAPK, GSK-3 and MKK1/2.
The p70S6K1 has been demonstrated to play a central role in tumor
growth by regulating pro-angiogenic effects and protein synthesis of
insulin [50,51]. In addition, targeting p70S6K1 gene expression by
micro-RNA 145 expression has been reported to inhibit tumor growth
[52]. Constitutively active STAT proteins, which are critical in the regu-
lation of cell cycle and cell growth, are found in various types of tumors
including breast cancer [53]. Previous studies have reported p38 MAPK
as a central kinase in a common intracellular signaling pathway that
plays an essential role in human breast cancer cell migration and inva-
sion by modulating the expression and activity of MMPs [54]. Further-
more, several lines of evidences suggest a link between p38 MAPK
activation and MMP-9 expression [55]. In some reports, the use of
pharmacological inhibitors of GSK-3 andof p38MAPK,which are proteins
with increased phosphorylation observed in our study, in MDA-MB-231
cells and in a model mouse of breast cancer demonstrated the key
requirement of these proteins in breast cancer development [56,
57]. Here, we also showed that MG-BSA-AGE-induced p70S6K1 over-
phosphorylation was prevented after RAGE neutralization, which fur-
ther removes all the biological effects of MG-BSA-AGEs-induced MDA-
MB-231 cell proliferation, migration and invasion. Thus, altogether,
targeting either the expression of phospho-proteins aforementioned
such as p70S6K1 or targeting RAGE expression might prevent the
progression and development of breast cancer in diabetic patients.
In conclusion, as a consequence of BSA glycation, this study demon-
strated the stimulatory effects ofMG-BSA-AGEs on cell proliferation,mi-
gration and invasion (with an enhancement ofMMP-9 activity) through
RAGE, in an invasive and non-hormone-dependent breast cancer cell
line MDA-MB-231. Among the phospho-proteins involved in MG-BSA-
AGE-induced signaling pathways, we also highlighted a concomitant
increase in the phosphorylation of p70S6K1, which might be a new
biomarker of the invasive subtype of the breast cancer and a promising
target drug like RAGE to ﬁght against breast cancer in diabetic patients.Acknowledgements
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